Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Andrew_Obenshain
|
| gptkbp:focusesOn |
rare diseases
gene therapy |
| gptkbp:formerName |
gptkb:Genetix_Pharmaceuticals
|
| gptkbp:founded |
1992
|
| gptkbp:founder |
gptkb:Nick_Leschly
gptkb:Mitchell_Finer gptkb:Philippe_Leboulch |
| gptkbp:headquartersLocation |
gptkb:Somerville,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bluebird Bio
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableAchievement |
FDA approval for Skysona
FDA approval for Zynteglo |
| gptkbp:numberOfEmployees |
~400 (2023)
|
| gptkbp:product |
gptkb:Zynteglo
gptkb:LentiGlobin gptkb:Skysona |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
lentiviral vector gene therapies
|
| gptkbp:stockSymbol |
gptkb:NASDAQ
gptkb:BLUE |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.bluebirdbio.com/
|
| gptkbp:bfsParent |
gptkb:Third_Rock_Ventures
|
| gptkbp:bfsLayer |
6
|